Axios Biosciences is revolutionizing oncology drug discovery by identifying drugs active in the tumor microenvironment, an important component of tumor biology where tumors interact with non-malignant tissue and can dramatically affect drug sensitivity. We are using these unique technologies, including one published in the journal Nature Medicine, to identify promising compounds for primary or metastatic cancers in the bone. Our ability to discover novel targets and active compounds, overlooked using traditional drug discovery approaches, can bridge the gap between preclinical research and clinical efficacy.